RMTI
ROCKWELL MEDICAL, INC.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$8.07
+1.96%Year over year
Reported trailing growth
- Revenue
- -21.1%
- EBITDA
- —
- EBIT
- —
- EPS
- -64.6%
- Free cash flow
- -42.6%
- Operating cash flow
- -17.2%
Forward estimates
Based on analyst estimates
- Revenue
- +8.6%
- EBITDA
- +141.3%
- EPS
- +64.4%
Three-year CAGR
- Revenue
- -1.7%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026